Pulmonary Embolism‐Attributable Mortality in Patients With Atherosclerotic Cardiovascular Disease in the United States from 2010 to 2023

Background Patients with atherosclerotic cardiovascular disease (ASCVD) are at increased risk of pulmonary embolism (PE) and related mortality, yet contemporary US trends remain incompletely defined. We examined PE‐attributable mortality from 2010 to 2023 among patients with ASCVD, stratified by age, sex, race, ethnicity, urbanization, and region. Methods We used the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research data (2010–2023) to assess PE‐attributable mortality among patients with ASCVD aged ≥15 years using age‐adjusted mortality rates. Concurrent trends in age‐adjusted ASCVD prevalence and risk factors were evaluated using NHANES (National Health and Nutrition Examination Survey). Age‐adjusted mortality rates were analyzed with Joinpoint regression to estimate average annual percentage change (95% CI), and trends in NHANES were assessed using linear models. Results From 2010 to 2023, 152 386 US patients with ASCVD aged ≥15 years (80 015 male, 72 371 female) died from PE. PE‐attributable AAMR rose from 3.62 to 4.96 per 100 000 (annual percentage change +3.1%; P <0.001), with a modest increase from 2010 to 2018 (annual percentage change +0.7%, P =0.003) and a sharp rise from 2018 to 2023 (annual percentage change +12.8%, P <0.001). Age‐adjusted mortality rate was highest in non‐Hispanic/non‐Latinx Black American individuals, and American Indian/Alaska Native and Hispanic/Latinx populations had the steepest increases. Adults <65 years, rural areas, and the Western United States showed disproportionate rises, whereas the South had the highest absolute deaths. Such trends paralleled increasing ASCVD prevalence, which was driven by hypertension, obesity, diabetes, and chronic kidney disease. Conclusions PE‐attributable mortality among US patients with ASCVD rose from 2010 to 2023 particularly among young‐to‐middle‐aged adults, socioeconomically isolated ethnic and racial groups, and Western residents.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-10-16
DOI
https://doi.org/10.1161/jaha.126.049510
Primary Topic
Venous Thromboembolism Diagnosis and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pulmonary Embolism‐Attributable Mortality in Patients With Atherosclerotic Cardiovascular Disease in the United States from 2010 to 2023

Samuel Zachary Goldhaber, Claudio Bilato, Gregory Piazza, Marco Zuin et al.
Journal of the American Heart Association
Venous Thromboembolism Diagnosis and Management
article

Pulmonary Embolism‐Attributable Mortality in Patients With Atherosclerotic Cardiovascular Disease in the United States from 2010 to 2023

Samuel Zachary Goldhaber, Claudio Bilato, Gregory Piazza, Marco Zuin, Gianluca Rigatelli
article en

Abstract

Background Patients with atherosclerotic cardiovascular disease (ASCVD) are at increased risk of pulmonary embolism (PE) and related mortality, yet contemporary US trends remain incompletely defined. We examined PE‐attributable mortality from 2010 to 2023 among patients with ASCVD, stratified by age, sex, race, ethnicity, urbanization, and region. Methods We used the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research data (2010–2023) to assess PE‐attributable mortality among patients with ASCVD aged ≥15 years using age‐adjusted mortality rates. Concurrent trends in age‐adjusted ASCVD prevalence and risk factors were evaluated using NHANES (National Health and Nutrition Examination Survey). Age‐adjusted mortality rates were analyzed with Joinpoint regression to estimate average annual percentage change (95% CI), and trends in NHANES were assessed using linear models. Results From 2010 to 2023, 152 386 US patients with ASCVD aged ≥15 years (80 015 male, 72 371 female) died from PE. PE‐attributable AAMR rose from 3.62 to 4.96 per 100 000 (annual percentage change +3.1%; P <0.001), with a modest increase from 2010 to 2018 (annual percentage change +0.7%, P =0.003) and a sharp rise from 2018 to 2023 (annual percentage change +12.8%, P <0.001). Age‐adjusted mortality rate was highest in non‐Hispanic/non‐Latinx Black American individuals, and American Indian/Alaska Native and Hispanic/Latinx populations had the steepest increases. Adults <65 years, rural areas, and the Western United States showed disproportionate rises, whereas the South had the highest absolute deaths. Such trends paralleled increasing ASCVD prevalence, which was driven by hypertension, obesity, diabetes, and chronic kidney disease. Conclusions PE‐attributable mortality among US patients with ASCVD rose from 2010 to 2023 particularly among young‐to‐middle‐aged adults, socioeconomically isolated ethnic and racial groups, and Western residents.

Journal of the American Heart Association
Brigham and Women's Hospital (US), Harvard University (US), University of Padua (IT), University of Ferrara (IT), Azienda Ospedaliero Universitaria Ospedali Riuniti (IT), International Renal Research Institute of Vicenza (IT)
Good health and well-being, Reduced inequalities
Openalex Percentile: Top 10%
Venous Thromboembolism Diagnosis and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.